VolitionRx Ltd
VNRX
25 hedge funds and large institutions have $9.51M invested in VolitionRx Ltd in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.4% → 0.38% (-0.02%)
4% less capital invested
Capital invested by funds: $9.9M → $9.51M (-$389K)
4% less funds holding
Funds holding: 26 → 25 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lagoda Investment Management
New York
|
+$136K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$85.6K |
| 3 |
Morgan Stanley
New York
|
+$40.8K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$32.4K |
| 5 |
Renaissance Technologies
New York
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
-$182K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$90.7K |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$81K |
| 4 |
VF
Virtu Financial
New York
|
-$35K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$259 |
VNRX Hedge Fund Activity: Q2 2019 in Review
25 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in VolitionRx Ltd (VNRX) for Q2 2019, worth a combined $9.51M — down 3.9% from $9.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VNRX and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 9 added.
The largest buyer was Lagoda Investment Management, adding an estimated $136K. The largest seller was Leisure Capital Management, cutting an estimated $182K.
- 25 institutional investors held VolitionRx Ltd (VNRX) as of Q2 2019, down from 26 in Q1 2019.
- Funds reported $9.51M of VolitionRx Ltd stock for Q2 2019, down 3.9% quarter-over-quarter.
- 1 fund opened new VolitionRx Ltd positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest VolitionRx Ltd buyer in Q2 2019 was Lagoda Investment Management, an estimated $136K added.
- The largest VolitionRx Ltd seller in Q2 2019 was Leisure Capital Management, an estimated $182K sold.
Based on aggregated 13F filings for Q2 2019.